Clinical Trial Update: CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updates for AUTO3 (CD19/22 CAR T cells) in B-cell acute lymphoblastic leukemia, including recurrent/refractory pediatric cases; study completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia
• Childhood Acute Lymphoblastic Leukemia

Drugs mentioned

• AUTO3 (CD19/CD22 CAR T cells)

Snippet

Sponsor: Autolus Limited | Conditions: B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-01